Guoxin Securities released a research report on April 22 stating that Huaheng Biotech (688639.SH) was given a purchase rating. The main reasons for the rating include: 1) net profit reached a record high in 2023, and the company's business performance was outstanding; 2) promoting the construction of new product projects with high quality and continuing to enrich the variety of products. (Mainichi Keizai Shimbun)
国信证券4月22日发布研报称，给予华恒生物（688639.SH）买入评级。评级理由主要包括：1）2023年净利润创新高，公司经营业绩表现靓丽；2）高质量推进新产品项目建设，持续丰富产品种类。（每日经济新闻）
Guoxin Securities released a research report on April 22 stating that Huaheng Biotech (688639.SH) was given a purchase rating. The main reasons for the rating include: 1) net profit reached a record high in 2023, and the company's business performance was
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.